Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1990 1
1991 2
1992 1
1993 1
1995 1
1996 1
1997 2
2000 1
2013 1
2014 5
2016 3
2017 2
2018 1
2022 3
2023 1

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.
NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee; Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, Katz DM, Keltner JL, Schron EB, Kupersmith MJ. NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee, et al. Among authors: kieburtz kd. JAMA. 2014 Apr 23-30;311(16):1641-51. doi: 10.1001/jama.2014.3312. JAMA. 2014. PMID: 24756514 Free PMC article. Clinical Trial.
Treating idiopathic intracranial hypertension--reply.
Wall M, McDermott MP, Kieburtz KD, Kupersmith MJ. Wall M, et al. Among authors: kieburtz kd. JAMA Neurol. 2014 Oct;71(10):1327-8. doi: 10.1001/jamaneurol.2014.2363. JAMA Neurol. 2014. PMID: 25322318 No abstract available.
Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M; Huntington Study Group SIGNAL investigators. Feigin A, et al. Among authors: kieburtz kd. Nat Med. 2022 Oct;28(10):2183-2193. doi: 10.1038/s41591-022-01919-8. Epub 2022 Aug 8. Nat Med. 2022. PMID: 35941373 Free PMC article. Clinical Trial.
Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M; Huntington Study Group SIGNAL investigators. Feigin A, et al. Among authors: kieburtz kd. Nat Med. 2022 Oct 4. doi: 10.1038/s41591-022-02070-0. Online ahead of print. Nat Med. 2022. PMID: 36195687 No abstract available.
Opicapone Pharmacokinetics and Effects on Catechol- O -Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa.
LeWitt P, Liang GS, Olanow CW, Kieburtz KD, Jimenez R, Olson K, Klepitskaya O, Loewen G. LeWitt P, et al. Among authors: kieburtz kd. Clin Neuropharmacol. 2023 Mar-Apr 01;46(2):43-50. doi: 10.1097/WNF.0000000000000538. Epub 2023 Jan 21. Clin Neuropharmacol. 2023. PMID: 36688497 Free PMC article. Clinical Trial.
27 results